Research Analysts Offer Predictions for BCYC Q1 Earnings

Bicycle Therapeutics plc (NASDAQ:BCYC) – Equities research analysts at HC Wainwright dropped their Q1 2025 earnings estimates for Bicycle Therapeutics in a report issued on Wednesday, February 26th. HC Wainwright analyst S. Ramakanth now anticipates that the company will earn ($0.99) per share for the quarter, down from their prior estimate of ($0.93). HC Wainwright has a “Buy” rating and a $33.00 price objective on the stock. The consensus estimate for Bicycle Therapeutics’ current full-year earnings is ($3.06) per share. HC Wainwright also issued estimates for Bicycle Therapeutics’ Q2 2025 earnings at ($0.99) EPS, FY2025 earnings at ($3.90) EPS, FY2026 earnings at ($4.31) EPS, FY2027 earnings at ($3.45) EPS, FY2028 earnings at ($1.56) EPS and FY2029 earnings at $1.20 EPS.

Other research analysts also recently issued research reports about the stock. JMP Securities dropped their target price on shares of Bicycle Therapeutics from $32.00 to $26.00 and set a “market outperform” rating for the company in a report on Wednesday, December 18th. Royal Bank of Canada reiterated an “outperform” rating and issued a $35.00 price target on shares of Bicycle Therapeutics in a research report on Friday, November 1st. Needham & Company LLC reiterated a “buy” rating and issued a $30.00 price target on shares of Bicycle Therapeutics in a research report on Wednesday. Stephens reissued an “equal weight” rating and issued a $15.00 price objective on shares of Bicycle Therapeutics in a research note on Wednesday, January 22nd. Finally, B. Riley decreased their price objective on shares of Bicycle Therapeutics from $28.00 to $17.00 and set a “neutral” rating for the company in a research note on Friday, December 13th. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $29.14.

Bicycle Therapeutics Stock Performance

Shares of Bicycle Therapeutics stock opened at $11.03 on Friday. The company has a market capitalization of $761.62 million, a P/E ratio of -3.35 and a beta of 0.93. The company has a fifty day moving average of $13.35 and a 200 day moving average of $19.46. Bicycle Therapeutics has a fifty-two week low of $10.91 and a fifty-two week high of $28.67.

Bicycle Therapeutics (NASDAQ:BCYC) last posted its quarterly earnings results on Tuesday, February 25th. The company reported ($0.75) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.10. The business had revenue of $3.70 million during the quarter, compared to analyst estimates of $5.47 million. Bicycle Therapeutics had a negative net margin of 450.64% and a negative return on equity of 27.35%. The company’s revenue was down 30.2% on a year-over-year basis. During the same period in the prior year, the business posted ($1.16) earnings per share.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of BCYC. Assetmark Inc. acquired a new position in shares of Bicycle Therapeutics during the 3rd quarter worth about $34,000. Barclays PLC grew its stake in Bicycle Therapeutics by 878.3% during the 4th quarter. Barclays PLC now owns 2,612 shares of the company’s stock valued at $37,000 after acquiring an additional 2,345 shares in the last quarter. Avior Wealth Management LLC purchased a new stake in Bicycle Therapeutics during the 4th quarter valued at about $57,000. China Universal Asset Management Co. Ltd. grew its stake in Bicycle Therapeutics by 30.7% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 9,329 shares of the company’s stock valued at $131,000 after acquiring an additional 2,191 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its stake in Bicycle Therapeutics by 26.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 8,424 shares of the company’s stock valued at $191,000 after acquiring an additional 1,782 shares in the last quarter. Institutional investors and hedge funds own 86.15% of the company’s stock.

Insiders Place Their Bets

In other Bicycle Therapeutics news, Director Bros. Advisors Lp Baker purchased 985,397 shares of the stock in a transaction on Friday, December 13th. The shares were bought at an average cost of $13.76 per share, with a total value of $13,559,062.72. Following the completion of the acquisition, the director now owns 9,537,643 shares in the company, valued at $131,237,967.68. This trade represents a 11.52 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CAO Travis Alvin Thompson sold 2,686 shares of the company’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $15.00, for a total transaction of $40,290.00. Following the completion of the transaction, the chief accounting officer now owns 32,146 shares of the company’s stock, valued at approximately $482,190. This trade represents a 7.71 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 27,677 shares of company stock valued at $392,413. 8.50% of the stock is currently owned by insiders.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.